These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1104 related articles for article (PubMed ID: 32469170)

  • 1. MicroRNA-98-5p Inhibits Tumorigenesis of Hepatitis B Virus-Related Hepatocellular Carcinoma by Targeting NF-κB-Inducing Kinase.
    Fei X; Zhang P; Pan Y; Liu Y
    Yonsei Med J; 2020 Jun; 61(6):460-470. PubMed ID: 32469170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long non-coding RNA F11-AS1 inhibits HBV-related hepatocellular carcinoma progression by regulating NR1I3 via binding to microRNA-211-5p.
    Deng Y; Wei Z; Huang M; Xu G; Wei W; Peng B; Nong S; Qin H
    J Cell Mol Med; 2020 Jan; 24(2):1848-1865. PubMed ID: 31880390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-548a-5p promotes proliferation and inhibits apoptosis in hepatocellular carcinoma cells by targeting Tg737.
    Zhao G; Wang T; Huang QK; Pu M; Sun W; Zhang ZC; Ling R; Tao KS
    World J Gastroenterol; 2016 Jun; 22(23):5364-73. PubMed ID: 27340352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus promotes proliferation and metastasis in male Chinese hepatocellular carcinoma patients through the LEF-1/miR-371a-5p/SRCIN1/pleiotrophin/Slug pathway.
    Bai PS; Hou P; Kong Y
    Exp Cell Res; 2018 Sep; 370(1):174-188. PubMed ID: 29928866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-424-5p acts as a potential biomarker and inhibits proliferation and invasion in hepatocellular carcinoma by targeting TRIM29.
    Du H; Xu Q; Xiao S; Wu Z; Gong J; Liu C; Ren G; Wu H
    Life Sci; 2019 May; 224():1-11. PubMed ID: 30876939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-183-5p contributes to malignant progression through targeting PDCD4 in human hepatocellular carcinoma.
    Duan X; Li W; Hu P; Jiang B; Yang J; Zhou L; Mao X; Tian B
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33078826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA SNHG7 accelerates the proliferation, migration and invasion of hepatocellular carcinoma cells via regulating miR-122-5p and RPL4.
    Yang X; Sun L; Wang L; Yao B; Mo H; Yang W
    Biomed Pharmacother; 2019 Oct; 118():109386. PubMed ID: 31545291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-486-5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1.
    Huang XP; Hou J; Shen XY; Huang CY; Zhang XH; Xie YA; Luo XL
    FEBS J; 2015 Feb; 282(3):579-94. PubMed ID: 25475121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway.
    Fu X; Wen H; Jing L; Yang Y; Wang W; Liang X; Nan K; Yao Y; Tian T
    Cancer Sci; 2017 Apr; 108(4):620-631. PubMed ID: 28132399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DANCR contributed to hepatocellular carcinoma malignancy via sponging miR-216a-5p and modulating KLF12.
    Wang J; Pu J; Zhang Y; Yao T; Luo Z; Li W; Xu G; Liu J; Wei W; Deng Y
    J Cell Physiol; 2019 Jun; 234(6):9408-9416. PubMed ID: 30430564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-222-3p induced by hepatitis B virus promotes the proliferation and inhibits apoptosis in hepatocellular carcinoma by upregulating THBS1.
    Sun Y; Shi P; Wu Q; Liu B; Yu Z; Jia H; Chang H
    Hum Cell; 2021 Nov; 34(6):1788-1799. PubMed ID: 34273068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-199a-5p suppresses tumorigenesis by targeting clathrin heavy chain in hepatocellular carcinoma.
    Huang GH; Shan H; Li D; Zhou B; Pang PF
    Cell Biochem Funct; 2017 Mar; 35(2):98-104. PubMed ID: 28261837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of circDYNC1H1 exhibits inhibitor effect on cell proliferation and migration in hepatocellular carcinoma through miR-140-5p.
    Wang ZY; Zhu Z; Wang HF; Qin B; Liu J; Yao XH; Li WC; Chen KS
    J Cell Physiol; 2019 Aug; 234(10):17775-17785. PubMed ID: 30864145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of DARS2 by HBV promotes hepatocarcinogenesis through the miR-30e-5p/MAPK/NFAT5 pathway.
    Qin X; Li C; Guo T; Chen J; Wang HT; Wang YT; Xiao YS; Li J; Liu P; Liu ZS; Liu QY
    J Exp Clin Cancer Res; 2017 Oct; 36(1):148. PubMed ID: 29052520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circ_0027089 regulates NACC1 by targeting miR-136-5p to aggravate the development of hepatitis B virus-related hepatocellular carcinoma.
    He W; Zhu X; Tang X; Xiang X; Yu J; Sun H
    Anticancer Drugs; 2022 Jan; 33(1):e336-e348. PubMed ID: 34419960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-κB-inducing kinase (NIK).
    Zhang S; Shan C; Kong G; Du Y; Ye L; Zhang X
    Oncogene; 2012 Aug; 31(31):3607-20. PubMed ID: 22105365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA H19 promotes the development of hepatitis B related hepatocellular carcinoma through regulating microRNA-22 via EMT pathway.
    Li L; Han T; Liu K; Lei CG; Wang ZC; Shi GJ
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5392-5401. PubMed ID: 31298392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-200c-5p suppresses proliferation and metastasis of human hepatocellular carcinoma (HCC) via suppressing MAD2L1.
    Li Y; Bai W; Zhang J
    Biomed Pharmacother; 2017 Aug; 92():1038-1044. PubMed ID: 28609841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long Noncoding RNA
    Gong X; Zhu Z
    Cancer Biother Radiopharm; 2020 Jun; 35(5):387-396. PubMed ID: 32315535
    [No Abstract]   [Full Text] [Related]  

  • 20. MiR-139-5p, miR-940 and miR-193a-5p inhibit the growth of hepatocellular carcinoma by targeting SPOCK1.
    Li P; Xiao Z; Luo J; Zhang Y; Lin L
    J Cell Mol Med; 2019 Apr; 23(4):2475-2488. PubMed ID: 30710422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.